Analysts Set OPKO Health, Inc. (NASDAQ:OPK) Price Target at $2.28

OPKO Health, Inc. (NASDAQ:OPK) has earned a consensus rating of “Hold” from the seven research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $2.2833.

A number of research analysts recently issued reports on the stock. Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday, October 30th. Zacks Research upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Wall Street Zen raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 1st. Jefferies Financial Group reaffirmed a “hold” rating and issued a $1.60 target price (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 533,300 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were bought at an average cost of $1.27 per share, for a total transaction of $677,291.00. Following the acquisition, the chief executive officer directly owned 214,966,448 shares in the company, valued at approximately $273,007,388.96. This trade represents a 0.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 49.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OPK. Oak Thistle LLC acquired a new position in shares of OPKO Health during the first quarter valued at about $26,000. Caprock Group LLC bought a new position in OPKO Health in the 3rd quarter valued at about $26,000. GM Advisory Group LLC acquired a new position in OPKO Health during the 1st quarter valued at about $33,000. Savant Capital LLC bought a new stake in OPKO Health during the 3rd quarter worth approximately $33,000. Finally, Cerity Partners LLC purchased a new stake in shares of OPKO Health in the first quarter worth approximately $36,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Stock Up 0.8%

Shares of NASDAQ:OPK opened at $1.28 on Wednesday. The company has a market capitalization of $982.66 million, a price-to-earnings ratio of -5.12 and a beta of 1.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The business’s 50-day moving average is $1.44 and its 200-day moving average is $1.37. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.05. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm’s revenue was down 12.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.03 earnings per share. Equities research analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.